Research graph
References from Enhancing Tumor Immunogenicity through Hyaluronic Acid-Mediated Delivery of Nonself Antigenic Peptides. Local targets link to admitted publications; unresolved targets remain external evidence.
CD8+ T-cell memory in tumor immunology and immunotherapy
10.1111/j.0105-2896.2006.00391.x · 2006 · External reference
A guide to antigen processing and presentation
10.1038/s41577-022-00707-2 · 2022 · External reference
Lymphocyte-mediated cytotoxicity
10.1146/annurev.immunol.20.100201.131730 · 2002 · External reference
Antigen-Presenting Cells: Potential of Proven und New Players in Immune Therapies
10.1159/000512729 · 2020 · External reference
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
10.1084/jem.183.1.87 · 1996 · External reference
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
10.1002/jcp.27782 · 2019 · External reference
Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens
10.1073/pnas.0914879107 · 2010 · External reference
Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens
10.1038/s41587-019-0390-x · 2020 · External reference
A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling
10.1038/cmi.2012.37 · 2013 · External reference
Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review
10.3390/cells12172159 · 2023 · External reference
Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignancies
10.1016/j.eclinm.2025.103378 · 2025 · External reference
Cancer antigens: immune recognition of self and altered self
10.1084/jem.180.1.1 · 1994 · External reference
Induction of anti-self-immunity to cure cancer
10.1016/0092-8674(95)90047-0 · 1995 · External reference
A guide to thymic selection of T cells
10.1038/s41577-023-00911-8 · 2024 · External reference
Serial triggering model
10.1007/978-0-387-09789-3_9 · 2008 · External reference
Structural basis for self-recognition by autoimmune T-cell receptors
10.1111/imr.12002 · 2012 · External reference
The regulatory network behind MHC class I expression
10.1016/j.molimm.2017.12.005 · 2019 · External reference
Regulation of MHC class II gene expression by the class II transactivator
10.1038/nri1708 · 2005 · External reference
Hyaluronan as tunable drug delivery system
10.1016/j.addr.2019.08.006 · 2019 · External reference
Hyaluronic Acid and Its Derivatives in Coating and Delivery Systems: Applications in Tissue Engineering, Regenerative Medicine and Immunomodulation
10.1002/adhm.201600316 · 2016 · External reference
Recent advances and prospects of hyaluronan as a multifunctional therapeutic system
10.1016/j.jconrel.2021.07.002 · 2021 · External reference
Modification of the antigenicity of cancer cells by conjugates consisting of hyaluronic acid and foreign antigens
10.1039/d3bm00439b · 2023 · External reference
Interaction between CD44 and highly condensed hyaluronic acid through crosslinking with proteins
10.1016/j.bioorg.2022.105666 · 2022 · External reference
Hyaluronan as an immune regulator in human diseases
10.1152/physrev.00052.2009 · 2011 · External reference
CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis
10.2174/156800911795655976 · 2011 · External reference
Chemical Modification of Hyaluronan and Their Biomedical Applications
10.3389/fchem.2022.830671 · 2022 · External reference
Hyaluronan conjugation of antigenic protein to modify immunogenic information
10.1016/j.stam.2006.05.010 · 2006 · External reference
Synthesis of novel polyampholyte comb-type copolymers consisting of a poly(L-lysine) backbone and hyaluronic acid side chains for a DNA carrier
10.1021/bc970213m · 1998 · External reference
Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy
10.1016/j.actbio.2017.11.010 · 2018 · External reference
PD-L1 siRNA-hyaluronic acid conjugate for dual-targeted cancer immunotherapy
10.1016/j.jconrel.2022.04.023 · 2022 · External reference
Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival
10.1016/j.biomaterials.2023.122006 · 2023 · External reference
A polymeric conjugate foreignizing tumor cells for targeted immunotherapy in vivo
10.1016/j.jconrel.2014.12.007 · 2015 · External reference
Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation
10.1016/j.molimm.2009.09.026 · 2009 · External reference
Immune Responses and Antitumor Effect through Delivering to Antigen Presenting Cells by Optimized Conjugates Consisting of CpG-DNA and Antigenic Peptide
10.1021/acs.bioconjchem.0c00523 · 2020 · External reference
Tyrosinase-Related Protein2 Peptide with Replacement of N-Terminus Residue by Cysteine Binds to H-2K(b) and Induces Antigen-Specific Cytotoxic T Lymphocytes after Conjugation with CpG-DNA
10.1021/acs.bioconjchem.2c00592 · 2023 · External reference
Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design
10.2741/a683 · 2001 · External reference
Genomic Classification of Cutaneous Melanoma
10.1016/j.cell.2015.05.044 · 2015 · External reference
Global burden of cutaneous melanoma incidence attributable to ultraviolet radiation in 2022
10.1002/ijc.35463 · 2025 · External reference
Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
1998 · External reference
In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program
10.4049/jimmunol.165.8.4731 · 2000 · External reference
Pembrolizumab versus Ipilimumab in Advanced Melanoma
10.1056/nejmoa1503093 · 2015 · External reference
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
10.1056/nejmoa1910836 · 2019 · External reference
Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies
10.1016/j.semcancer.2019.12.005 · 2020 · External reference
Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery
10.1016/j.biomaterials.2011.01.067 · 2011 · External reference
Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay
10.1038/nm1001-1159 · 2001 · External reference
Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb
10.1126/science.1323877 · 1992 · External reference
Improved survival with ipilimumab in patients with metastatic melanoma
10.1056/nejmoa1003466 · 2010 · External reference
Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy
10.3389/fimmu.2026.1808146 · 2026 · External reference
Spatio-temporal patterns of pancreatic cancer cells expressing CD44 isoforms on supported membranes displaying hyaluronic acid oligomers arrays
10.1371/journal.pone.0042991 · 2012 · External reference
Structure, function and role of CD44 in neoplasia
10.4103/jomfp.jomfp_246_18 · 2019 · External reference
CD44: A multifunctional mediator of cancer progression
10.3390/biom11121850 · 2021 · External reference
The state of CD44 activation in cancer progression and therapeutic targeting
10.1111/febs.16179 · 2022 · External reference
Identification of hyaluronan receptor for endocytosis (HARE)
10.1074/jbc.m003030200 · 2000 · External reference
Characterization of a functional hyaluronan-binding domain from the human CD44 molecule expressed in Escherichia Coli
10.1006/prep.1998.0971 · 1998 · External reference
Molecular weight specific impact of soluble and immobilized hyaluronan on CD44 expressing melanoma cells in 3D collagen matrices
10.1016/j.actbio.2016.12.026 · 2017 · External reference
Hyaluronic acid: known for almost a century, but still in vogue
10.3390/pharmaceutics14040838 · 2022 · External reference
A PEGylated hyaluronic acid conjugate for targeted cancer immunotherapy
10.1016/j.jconrel.2017.08.032 · 2017 · External reference
Interferons alpha and beta in cancer: therapeutic opportunities from new insights
10.1038/s41573-018-0011-2 · 2019 · External reference
Endogenous retroviruses in the origins and treatment of cancer
10.1186/s13059-021-02357-4 · 2021 · External reference
